Conjugated Estrogen cream is indicated for the management of:

• Moderate to severe vasomotor symptoms associated with estrogen deficiency.
• Prevention and treatment of osteoporosis due to estrogen deficiency.
• Atrophic vaginitis and Kraurosis vulvae.
• Female hypoestrogenism.
• Moderate to severe dyspareunia.

Conjugated estrogens for vaginal use are a mixture of naturally derived estrogens obtained primarily from pregnant mares’ urine and blended to reflect a standard composition. They consist of sodium salts of water-soluble sulfate esters of estrone, equilin, and 17α-dihydroequilin, along with small amounts of other estrogenic compounds including 17α-estradiol, equilenin, 17β-estradiol, and related derivatives.

Estrogens are essential for the development and maintenance of the female reproductive system and secondary sexual characteristics. They support the growth of the vagina, uterus, fallopian tubes, and breast tissue. They also influence skeletal development, maintain urogenital tissue elasticity, regulate epiphyseal closure, and contribute to secondary sexual traits such as body hair distribution and pigmentation. Estrogens regulate the menstrual cycle and influence pituitary gonadotropin secretion. Conjugated estrogens act similarly to endogenous estrogens. In target tissues such as the reproductive organs, breasts, hypothalamus, and pituitary, they enter cells and activate gene transcription, leading to RNA and protein synthesis.

Osteoporosis associated with estrogen deficiency: Estrogen replacement therapy is effective in preventing postmenopausal osteoporosis by reducing bone resorption and slowing bone loss. Even when initiated years after menopause, it can prevent further loss of bone mass, although it does not restore previously lost bone. The protective effect continues only during active therapy. Risk varies among different ethnic groups.

Atrophic vaginitis and Kraurosis Vulvae :These conditions result from estrogen deficiency. Lack of estrogen causes thinning, drying, and shrinkage of vulvar and vaginal tissues, with loss of normal vaginal folds. Symptoms may include irritation, itching, painful urination, and dyspareunia. Minor bleeding or fissures may occur during intercourse. These changes are reversible with estrogen therapy.

Female Hypoestrogenism :Estrogen therapy is indicated in hypoestrogenism due to ovarian failure or hypogonadism. Early ovarian failure may delay bone maturation and epiphyseal closure. Long-term deficiency increases the risk of osteoporosis. Treatment helps restore and maintain secondary female sexual characteristics.

Atrophic Vaginitis and Kraurosis Vulvae Atrophic Vaginitis and Kraurosis Vulvae: Administer cyclic regimen (daily for 21 days followed by 7 days off) intravaginally. Start at 0.5 gm dosage strength; may adjust dosage (0.5 to 2 gm) based on individual response.

Moderate to Severe Dyspareunia Moderate to Severe Dyspareunia: Treats symptom of vulvar and vaginal atrophy due to menopause. 0.5 gm intravaginally in a twice-weekly (e.g., Monday and Thursday) continuously or in a cyclic regimen of daily administration for 21 days followed by 7 days off.

Step 1: Remove cap from tube.
Step 2: Screw nozzle end of applicator onto tube.
Step 3: Gently squeeze tube from the bottom to force sufficient cream into the barrel to provide the prescribed dose.
Step 4: Unscrew applicator from tube.
Step 5: Place the applicator into the vaginal opening.
Step 6: To deliver medication, press plunger downward.

To cleanse: Pull plunger to remove it from barrel. Wash with mild soap and warm water. Do not boil.

Rifampin has been reported to reduce estrogenic activity when used together with estrogen therapy. This effect is believed to occur due to increased metabolism of estrogen, likely through induction of hepatic microsomal enzymes.

Conjugated Estrogen vaginal cream is contraindicated in patients with:

• Known or suspected breast cancer.
• Known or suspected estrogen-dependent tumors.
• Known or suspected pregnancy.
• Undiagnosed abnormal genital bleeding.
• Active thrombophlebitis or thromboembolic disorders.
• Hypersensitivity to any component of the product.

Serious adverse effects are described under warnings and precautions. Additional reported side effects include:

• Genitourinary: Breakthrough bleeding, spotting, changes in menstrual flow, amenorrhea.
• Breasts: Tenderness, enlargement, nipple discharge.
• Gastrointestinal: Nausea, vomiting, abdominal cramps, bloating, cholestatic jaundice.
• Skin: Chloasma/melasma (may persist after discontinuation), alopecia, rash.
• Eyes: Changes in corneal curvature, contact lens intolerance.
• CNS: Headache, migraine, dizziness, chorea.
• Others: Weight changes, edema, libido changes, worsening of porphyria.

Common side effects: headache, breast pain, irregular vaginal bleeding or spotting, abdominal cramps, bloating, nausea, vomiting, hair loss, fluid retention, vaginal yeast infection, and local irritation such as burning, itching, or discomfort.

Uncommon but serious side effects: heart attack, stroke, blood clots, dementia, breast cancer, endometrial (uterine lining) cancer, ovarian cancer, hypertension, hyperglycemia, gallbladder disease, fibroid enlargement, and severe allergic reactions.

Estrogen should not be used during pregnancy. Exposure during pregnancy may increase the risk of congenital abnormalities in male and female reproductive organs, vaginal adenosis, cervical dysplasia, and later development of vaginal cancer in females. There is no clinical indication for estrogen use during pregnancy.

Estrogens may pass into breast milk; therefore, use during lactation should be avoided unless clearly necessary.

Estrogen therapy without progesterone in women with an intact uterus may increase the risk of endometrial hyperplasia and carcinoma. This risk depends on dose and duration of therapy. Regular evaluation is required at least once yearly. Adding a progestogen reduces this risk.

Possible additional risks include effects on carbohydrate and lipid metabolism, and increased risk of gallbladder disease. Some studies suggest a possible increased risk of breast cancer with long-term high-dose use. Regular breast examination and self-examination are recommended. Full medical and family history should be taken before starting therapy. Routine examinations should include blood pressure, breast, abdominal, and pelvic examination along with Pap smear. Unexplained vaginal bleeding should be evaluated, and dose adjustment may be required. Caution is advised in patients with liver impairment due to altered estrogen metabolism.

Estrogen overdose may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness, fatigue, and withdrawal bleeding in women. Treatment involves stopping the medication and providing supportive care.

Female sex hormones

Store in a cool place below 30°C, in a dry environment, protected from light and moisture.